Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.61 |
| ▸ | RELA | Q04206 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30721522 | 1.00 | NOTUM (0.67) | NOTUMRAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL30039812 | 0.90 | NOTUM (0.69) | NOTUML3MBTL1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL926908 | 0.90 | NOTUM (0.69) | NOTUML3MBTL1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL30401717 | 0.89 | NOTUM (0.67) | NOTUML3MBTL1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL9530206 | 0.89 | NOTUM (0.62) | NOTUMSMN1; SMN2MAPTALDH1A1TSHR | |
| SCHEMBL2116912 | 0.83 | NPC1 (0.71) | NOTUMRAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL29554766 | 0.83 | NPC1 (0.71) | NOTUMRAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL30681385 | 0.83 | RAB9A (0.66) | NOTUMRAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL12282796 | 0.82 | NOTUM (0.67) | NOTUMRAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL30900483 | 0.82 | NOTUM (0.61) | NOTUMRAB9ANPC1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894327-A | Process for preparing indoline carboxylic ester | 阿拉善盟锦源科技发展有限公司 | 2023-04-04 | — | — | CN | claimed |
| EP-3204347-B1 | ENAMINE COMPOUNDS FOR PROTECTING AGAINST UV RADIATION | COMMW SCIENT IND RES ORG (AU) | 2024-10-23 | — | — | EP | disclosed |
| EP-3670515-B1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-115894327-A | Process for preparing indoline carboxylic ester | 阿拉善盟锦源科技发展有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115894327-A | Process for preparing indoline carboxylic ester | 阿拉善盟锦源科技发展有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11512042-B2 | Enamine compounds for absorbance of electromagnetic energy | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2022-11-29 | — | — | US | disclosed |
| CN-107108429-B | Compound (I) | 联邦科学与工业研究组织 | 2022-08-19 | — | — | CN | disclosed |
| US-11024812-B2 | Compound for organic-electric element, organic-electric element using same, and electronic device for same | DUK SAN NEOLUX CO., LTD. (KR) | 2021-06-01 | — | — | US | disclosed |
| US-11024812-B2 | Compound for organic-electric element, organic-electric element using same, and electronic device for same | DUK SAN NEOLUX CO., LTD. (KR) | 2021-06-01 | — | — | US | disclosed |
| EP-3738964-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| CN-1374349-A | Process for producing asymmetric hypomethyl dye | BAYER AG (DE) | 2002-10-16 | — | — | CN | disclosed |
| EP-0687251-B1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI SYNTHELABO (FR) | 2002-02-27 | — | — | EP | disclosed |
| US-5773612-A | VASOPRESSIN OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5594023-A | 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-01-14 | — | — | US | disclosed |
| EP-0687251-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995018105-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-07-06 | — | — | WO | disclosed |
| US-5401738-A | Angiotensin antagonist, hypotensive, aldosteronism, cardiac insufficiency | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER (DE) | 1995-03-28 | — | — | US | disclosed |
| CN-1082542-A | Benzimidizole derivatives | MERCK PATENT GMBH (DE) | 1994-02-23 | — | — | CN | disclosed |
| EP-0574787-A2 | Benzimidazole derivatives as angiotensin II antagonists | MERCK PATENT GmbH (DE) | 1993-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024812-B2 | Compound for organic-electric element, organic-electric element using same, and electronic device for same | PIEZO1, OR10J3, OR51E2 | NOTUM 73/4885RAB9A 3738/4885NPC1 3510/4885 |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | KCNH2, KCNH3, KCNQ1 | NOTUM 2404/4885RAB9A 1857/4885NPC1 189/4885 |
| US-11512042-B2 | Enamine compounds for absorbance of electromagnetic energy | ENO1, NQO1, NNMT | NOTUM 4567/4885RAB9A 2329/4885NPC1 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.